SK pharmteco Qualifies Commercial-Scale Viral Vector Facility in France

New state-of-the-art plant in Corbeil-Essonnes now fully operational to support late-stage and commercial viral vector programs.

Mar. 12, 2026 at 8:04am

Got story updates? Submit your updates here. ›

SK pharmteco, a global contract development and manufacturing organization (CDMO), has announced the successful CGMP qualification of its new manufacturing facility in Corbeil-Essonnes, France. The state-of-the-art plant is now fully operational and prepared to support late-stage and commercial viral vector programs at scale, after being inspected and approved by the French Health Authority (ANSM).

Why it matters

The qualification of this new facility marks a crucial milestone for SK pharmteco and its partners, as it eliminates the traditional 'readiness gap' between clinical and commercial manufacturing. By providing a fully inspected and approved environment that mirrors their development workflows, SK pharmteco's clients can now scale from preclinical stages to commercial supply with the same teams, platforms, and systems, ensuring total continuity and faster speed-to-market.

The details

The new 5,000 m² purpose-built CGMP facility is specifically designed for reproducibility and scale, offering two multiproduct and independent manufacturing facilities, two independent viral vector production suites, and 12 single-use bioreactors from 50 L to 1,000 L providing a total installed upstream capacity of 5,000 L. The facility has the capacity for up to 40 cGMP batches per year, supporting parallel processing and reliable supply. By leveraging its established AAVelocity™ and LentiSure™ platforms, SK pharmteco ensures that processes running at a clinical scale remain reliable and steady when scaled up to larger commercial volumes, greatly reducing the risks for cell and gene therapy developers.

  • The facility was inspected by the ANSM (French Health Authority) and successfully approved for operations in March 2026.
  • The facility has since produced its first batch using SK pharmteco's proprietary AAVelocity™ platform.

The players

SK pharmteco

A global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and South Korea. The company's core capabilities center on small molecules, peptides, and viral vectors, providing the specialized expertise needed to bring complex therapies to market.

ANSM

The French Health Authority, which inspected and approved the SK pharmteco facility in Corbeil-Essonnes, France for operations.

Joerg Ahlgrimm

The CEO of SK pharmteco.

Got photos? Submit your photos here. ›

What they’re saying

“The qualification of this new facility marks a crucial milestone for SK pharmteco and our partners. By providing a fully inspected and approved environment that mirrors our development workflows, we eliminate the traditional 'readiness gap.' Our clients can now scale from preclinical stages to commercial supply with the same teams, the same platforms, and the same systems, ensuring total continuity and faster speed-to-market.”

— Joerg Ahlgrimm, CEO of SK pharmteco

The takeaway

This new facility in France enhances SK pharmteco's position as a leading global partner in viral vector manufacturing, providing clients with a seamless transition from clinical to commercial production and addressing critical pain points in the viral vector market, such as regulatory confidence and operational continuity.